PT-2385

For research use only. Not for therapeutic Use.

  • CAT Number: I002185
  • CAS Number: 1672665-49-4
  • Molecular Formula: C₁₇H₁₂F₃NO₄S
  • Molecular Weight: 383.34
  • Purity: ≥95%
Inquiry Now

PT-2385 (Cat.No:I002185) is an investigational drug targeting hypoxia-inducible factor 2-alpha (HIF-2α), a protein involved in tumor growth and progression. As a HIF-2α inhibitor, PT-2385 has shown promise in preclinical studies for the treatment of clear cell renal cell carcinoma (ccRCC) and other HIF-2α-driven cancers. Clinical trials are ongoing to assess its efficacy and safety in cancer therapy.


Catalog Number I002185
CAS Number 1672665-49-4
Synonyms

PT-2385; PT 2385;PT2385

Molecular Formula C₁₇H₁₂F₃NO₄S
Purity ≥95%
Target HIF/HIF Prolyl-Hydroxylase
Solubility 10 mM in DMSO
Storage 3 years -20℃ powder
IUPAC Name 3-[[(1S)-2,2-difluoro-1-hydroxy-7-methylsulfonyl-1,3-dihydroinden-4-yl]oxy]-5-fluorobenzonitrile
InChI InChI=1S/C17H12F3NO4S/c1-26(23,24)14-3-2-13(12-7-17(19,20)16(22)15(12)14)25-11-5-9(8-21)4-10(18)6-11/h2-6,16,22H,7H2,1H3/t16-/m0/s1
InChIKey ONBSHRSJOPSEGS-INIZCTEOSA-N
SMILES CS(=O)(=O)C1=C2C(C(CC2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)(F)F)O
Reference

1. Cell Death Dis. 2017 Oct 12;8(10):e3095. doi: 10.1038/cddis.2017.411. <br />
<br />
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of
sorafenib by suppressing hepatocellular carcinoma invasion via alteration of
pSTAT3, pAKT and pERK signals. <br />
<br />
Xu J(1), Zheng L(1), Chen J(1), Sun Y(2), Lin H(1), Jin RA(1), Tang M(3), Liang
X(1), Cai X(1). <br />
Author information: <br />
(1)Key Laboratory of Endoscopic Technique Research of Zhejiang Province,
Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University,
Hangzhou 310016, China.
(2)Department of Radiation Oncology, University of Rochester Medical Center,
Rochester, NY 14642, USA.
(3)Department of Reproductive Endocrinology, Women/’s Hospital, School of
Medicine, Zhejiang University, Hangzhou 310006, China. <br />
<br />
Although sorafenib is currently used as a standard treatment for advanced
hepatocellular carcinoma, low response rate, transient and limited efficacy,
primary and acquired resistance and negative side-effects gain increasing
attentions, suggesting the need for better efficacious combination therapy. Here,
we demonstrated that the sorafenib-induced or hypoxia-induced hypoxia inducible
factor (HIF)-2α could bind to an hypoxia responsive element within 500&#8201;bp region
of androgen receptor (AR) promoter and thus transcriptionally suppress AR.
Importantly, In vitro and In vivo studies suggested a specific and potent HIF-2α
inhibitor, PT-2385, could significantly enhance sorafenib efficacy by suppressing
HIF-2α, increasing AR and suppressing downstream pSTAT3/pAKT/pERK pathways.
Clinical samples further confirmed the role of HIF-2α and AR. It is promising
that PT-2385 could alleviate the undesirable side-effects of sorafenib treatment
by sorafenib-PT-2385 combination therapy, which may shed light for late-stage HCC
patients.

Request a Quote